| Date: | 2010-05-10 |
| Biotech partner: | Intercell (Austria) |
| Pharma Partner: | Boehringer Ingelheim Vetmedica (Germany) |
| Type of agreement: | * R&D * licensing |
| Compound: | antigens derived from Intercell’s Antigen Identification Program (AIP®) to develop animal vaccines Intercell's AIP® has already been used to identify relevant and protective antigens for several bacterial pathogens including Staphylococcus aureus and epidermidis, Streptococcus pneumoniae, Streptococcus agalactiae and pyogenes, Enterococcus faecalis, Klebsiella pneumoniae, Borrelia spp., ETEC, Shigella, Campylobacter jejuni, non-typable Haemophilus influenzae, and Moraxella catarrhalis. |
| Disease area: | undisclosed animal diseases |
| Nature of the agreement: | Intercell AG has entered into a worldwide Option and Exclusive License Agreement under which Boehringer Ingelheim Vetmedica has the right to use certain antigens derived from Intercell’s Antigen Identification Program (AIP®) to develop animal vaccines. |
| Financial terms of the agreement: | Under the agreement, Intercell will receive upfront, option and milestone payments as well as royalties on product net sales. |
